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Objectives. We sought to assess the possible relations between
clinical severity of chronic heart failure and catabolic factors,
specifically tumor necrosis factor (TNF), soluble TNF receptors 1
and 2 (sTNFR-1 and sTNFR-2), cortisol, testosterone and dehy-
droepiandrosterone (DHEA).
Background. Chronic heart failure is associated with loss of
muscle bulk that may be related to alteration of the balance
between catabolism and anabolism.
Methods. Sixty-three patients (average age 6SD 60.4 6 11.3
years) with stable chronic heart failure and 20 control subjects
aged 52.8 6 11.4 years were studied. We measured body mass
index (BMI) and obtained maximal incremental exercise testing
with metabolic gas exchange measurements and measurements of
venous levels of TNF, sTNFR-1 and sTNFR-2, cortisol and DHEA.
Results. There was no difference in total TNF-alpha levels
between patients and control subjects (9.76 6 8.59 vs. 6.84 6
2.7 pg/ml). sTNFR-1 (128.9 6 84.5 vs. 63.6 6 23.3 pg/ml, p <
0.003) and sTNFR-2 (250.1 6 109.5 vs. 187.9 6 92.2 pg/ml, p 5
0.03) were higher in patients. DHEA was lower in patients (9.88 6
6.94 vs. 15.64 6 8.33 nmol/liter, p 5 0.004). The ratio of log
cortisol to log DHEA correlated with log TNF level (r 5 0.50, p <
0.001 for the patients alone; r 5 0.48, p < 0.001 for the group as
a whole). Peak oxygen consumption correlated with both sTNFR-1
and sTNFR-2 (r 5 20.51, p < 0.001 and r 5 20.39, p < 0.001,
respectively). There was a negative correlation between BMI and
TNF levels (r 5 20.43, p < 0.001 for the patients) and the
cortisol/DHEA ratio (r 5 20.32, p 5 0.01 for the patients).
Conclusions. There is an increase in TNF and its soluble
receptors in chronic heart failure. This increase is associated with
a rise in the cortisol/DHEA (catabolic/anabolic) ratio. These
changes correlate with BMI and clinical severity of heart failure,
suggesting a possible etiologic link.
(J Am Coll Cardiol 1997;30:997–1001)
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The origin of the weight loss and cachexia seen in patients with
chronic heart failure is still unclear. Evidence of muscle
wasting is present even in mild chronic heart failure (1), and
the muscle wasting appears to be related to exercise capacity
(2). Cachectic patients with chronic heart failure are weaker
than noncachectic patients despite having similar conventional
measures of disease severity (3). Possible mediators of weight
loss include inflammatory cytokines, and interest has focused
on the possible role of tumor necrosis factor-alpha (TNF-
alpha) (4,5). TNF may have further significance as a myocar-
dial depressant (6,7). TNF-alpha appears to mediate its bio-
logic effects by way of two different cell membrane receptors
(8). The TNF-binding portion of the receptors can be found in
solution, known as sTNFR-1 and sTNFR-2. The soluble recep-
tors are increased after acute myocardial infarction (9). Some
investigators (10) have found an increase in the sTNFRs in
chronic heart failure with a reduction in cardiac myocyte–
bound receptors.
Other possible mediators of weight loss include alterations
in adrenal hormone metabolism. In tuberculosis, wasting is
associated with an increase in the ratio between cortisol and
the anabolic hormone, dehydroepiandrosterone (DHEA) (11).
Whether this change in steroid metabolism is caused by TNF
activation is not clear (12), but it may be related to patterns of
immune activation (13).
We set out to examine the possible relations between TNF,
its receptors and the generalized neurohormonal activation of
chronic heart failure. We also investigated the possible role of
altered steroid metabolism and, in particular, the cortisol/
DHEA ratio as a measure of the endocrine balance between
anabolism and catabolism. Testosterone, another anabolic
steroid, was also measured. We also attempted to relate any
changes we found to the clinical state and exercise perfor-
mance of the patients.
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Methods
The study was approved by the ethics committee of the
Royal Brompton National Heart and Lung Hospital. All
subjects gave fully informed signed consent.
We studied 63 patients (average age 6 SD 60.4 6 11.3
years) and 20 control subjects aged 52.8 6 11.4 years. Of the
patients, 26 had dilated cardiomyopathy and the other 37 had
ischemic cardiomyopathy. Baseline demographic data are
shown in Table 1. All patients had been clinically stable for a
minimum of 3 months before study. No patient was edematous
and all were on a medication regimen that had not changed for
$2 months. No patient had either infection or neoplastic
disease at the time of investigation. The average dose of
diuretic agent used was 115.6 6 95.9 mg daily (where 1 mg of
bumetanide was considered equivalent to 40 mg of furo-
semide). Twelve patients were not taking an angiotensin-
converting enzyme inhibitor. Of the others, 24 were receiving
captopril, 21 enalapril, 5 lisinopril and 1 ramipril. Twenty-three
patients were receiving digoxin, 17 amiodarone, 22 warfarin
and 24 aspirin. All patients were limited by either breathless-
ness or fatigue, or both.
Control subjects were recruited from hospital staff members
and subjects presenting for a routine health examination.
Subjects were only used as control subjects if they had no past
medical history of cardiac or pulmonary or neoplastic disease
and if a rest electrocardiogram and pulmonary function tests
were normal.
Height and nude weight were measured in all subjects.
Subjects underwent maximal incremental exercise testing using
a standard Bruce protocol with the addition of a stage 0, that
is, 3 min at 1.7 km/h at zero gradient. Patients breathed
through a one-way valve connected to a respiratory mass
spectrometer (Innovision, Odense, Denmark). Ventilation
(V˙E), oxygen consumption (V˙O2) and carbon dioxide produc-
tion (V˙CO2) were measured on-line every 10 s. Exercise was
started after basal readings had been stable for $2 min.
Subjects were encouraged to exercise to exhaustion. Peak V˙O2
was taken as an index of exercise capacity. The slope of the
relation between ventilation and carbon dioxide production
(V˙E/V˙CO2 slope) was calculated from the exercise data and
taken as an index of the ventilatory response to exercise.
Blood samples were taken for hormone and cytokine assay
before the exercise test. Blood was withdrawn between 9 and
10 AM after a 12-h fast in a quiet, darkened room. A polyeth-
ylene cannula was inserted into an antecubital vein, and blood
was withdrawn after the subject had been lying supine for
20 min. Blood was centrifuged immediately and serum stored
at 270°C for later analysis. Blood was also analyzed for serum
creatinine, urea, albumin and total protein as indexes of
nutritional state.
Radioimmunoassays were performed for renin (Biodata,
Gudonia Montecelio, Italy) and aldosterone (DPC). Cat-
echolamines were measured by high performance liquid chro-
matography. TNF was measured by an ELISA assay with a
lower limit of detectability of 3.0 pg/ml (Medgenix, Fleurus,
Belgium) which measured total TNF, both free and bound to
soluble receptors. sTNFR-1 (lower limit of detection 25 pg/ml)
and sTNFR-2 (lower limit of detection 2 pg/ml) were measured
by using test kits from R&D Systems. Cortisol was measured
using an ELISA assay (Boeringer Mannheim, Germany) and
DHEA was measured by radioimmunoassay with a lower limit
of detectability of 0.04 ng/ml (DPC).
Statistical methods. Comparisons between patients and
control subjects were made by Student t test. The cytokine
measurements were log-normally distributed, and comparisons
were made between sets of log-transformed data. Linear
regression using the least squares method was used to establish
correlations between variables.
Results
All subjects managed to exercise to a point where the
respiratory exchange ratio (V˙CO2/V˙O2) exceeded 1.0, indicating
that at least near maximal exercise capacity was reached.
Patients had a lower peak V˙O2 and higher V˙E/V˙CO2 slope than
control subjects. There was no significant difference in the
V˙CO2/V˙O2 ratio achieved at peak exercise.
There was evidence of general activation of the sympathetic
Abbreviations and Acronyms
BMI 5 body mass index
DHEA 5 dehydroepiandrosterone
NYHA 5 New York Heart Association
sTNFR 5 soluble tumor necrosis factor receptor
TNF 5 tumor necrosis factor
V˙CO2 5 carbon dioxide production
V˙E 5 ventilation
V˙O2 5 oxygen consumption
Table 1. Baseline Data for Patients and Control Subjects
Patients
(n 5 63)
Control
Subjects
(n 5 20)
p
Value*
Age (yr) 60.4 6 11.3 52.8 6 11.4 . 0.01
BMI (kg/m2) 25.4 6 4.2 26.4 6 3.9 NS
LVEF (%) 27.4 6 15.3 . . . . . .
NYHA class
I 6 . . . . . .
II 18 . . . . . .
III 31 . . . . . .
IV 8 . . . . . .
Peak V˙O2 (ml/min per kg) 17.2 6 6.3 36.7 6 7.5 , 0.001
V˙E/V˙CO2 37.0 6 13.7 25.1 6 3.4 , 0.001
RER (peak) 1.14 6 0.15 1.21 6 0.10 0.07
*Unpaired t test comparisons between the two groups. Data presented are
mean value 6 SD or number of patients. BMI 5 body mass index; LVEF 5 left
ventricular ejection fraction by radionuclide ventriculogram; NYHA 5 New
York Heart Association classification of symptoms in chronic heart failure;
RER 5 respiratory exchange ratio at peak exercise; V˙E/V˙CO2 5 slope of the
relation between ventilation and carbon dioxide production; V˙O2 5 oxygen
consumption.
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and renin-angiotensin systems in patients with chronic heart
failure (Table 2) with higher levels of aldosterone (729.4 6
695.3 vs. 283.5 6 167.2 pmol/liter, p 5 0.006), renin (12.06 6
13.27 vs. 1.36 6 0.71 ng/ml per h, p 5 0.001), norepinephrine
(3.67 6 2.5 vs. 1.77 6 0.72 nmol/liter, p 5 0.001) and
epinephrine (1.38 6 1.68 vs. 0.50 6 0.16 mmol/liter, p 5 0.022)
than in control subjects. Urea and creatinine were higher in the
patients (Table 3). Albumin was lower and total protein higher
in the patients.
Levels of TNF were not significantly higher in the patients,
but levels of both TNF receptors were higher in patients than
in control subjects. There were no differences in cytokine levels
between patients with ischemic versus idiopathic cardiomyop-
athy.
Within the patient group, levels of the two TNF receptors
correlated (r 5 0.80, p , 0.001) and each correlated with the
level of TNF (sTNFR-1, r 5 0.57, p , 0.001; sTNFR-2, r 5
0.52, p , 0.001). These correlations were unchanged when
recalculated for the group as a whole (r 5 0.83, r 5 0.50 and
r 5 0.44, respectively, p , 0.001 for the three comparisons).
The log[cortisol]/log[DHEA] ratio was higher in patients than
in control subjects, but there was no difference between the
two groups in testosterone and estradiol levels. The ratio of log
[cortisol]/log[DHEA] correlated with log[TNF] level (r 5 0.50,
p , 0.001 for the patients alone; r 5 0.48, p , 0.001 for the
group as a whole) (Fig. 1).
Relations with clinical variables. There was no relation
between left ventricular ejection fraction and any of the
cytokines measured. There was a relation between peak V˙O2
and both sTNFR-1 and sTNFR-2 (r 5 20.54, p , 0.001 and
Figure 1. Relation between TNF and cortisol/DHEA ratio obtained
by using a log:log plot.
Table 2. Results of Cytokine Assays With Log Transformed Data
Patients
(n 5 63)
Control
Subjects
(n 5 20)
p
Value*
Results of Cytokine Assays
Cortisol (nmol/liter) 413.2 6 107.4 370.1 6 109.2
DHEA (nmol/liter) 9.88 6 6.94 15.64 6 8.33 0.004
Cortisol/DHEA ratio 69.60 6 62.37 44.02 6 77.01
Testosterone (nmol/liter) 11.20 6 5.92 10.00 6 3.01
Estradiol (pmol/liter) 65.29 6 48.78 47.89 6 31.97
Total TNF-alpha (pg/ml) 9.76 6 8.59 6.84 6 2.7 NS
sTNFR-1 (pg/ml) 128.9 6 84.5 63.6 6 23.3 , 0.003
sTNFR-2 (pg/ml) 250.1 6 109.5 187.9 6 92.2 0.03
Log Transformed Data
log[cortisol] 2.60 6 0.11 2.55 6 0.13 NS
log[DHEA] 0.89 6 0.31 1.11 6 0.34 0.01
log[cortisol]/log[DHEA] ratio 1.71 6 0.34 1.45 6 0.35 0.009
log[testosterone] 0.95 6 0.38 0.98 6 0.15 NS
log[estradiol] 1.69 6 0.35 1.57 6 0.35 NS
log[TNF-alpha] 0.87 6 0.35 0.81 6 0.17 NS
log[sTNFR-1] 3.04 6 0.26 2.75 6 0.23 0.0001
log[sTNFR-2] 3.36 6 0.18 3.21 6 0.27 0.009
*Unpaired t test comparisons between the two groups. Data presented are mean value 6 SD. DHEA 5
dehydroepiandrosterone; sTNFR 5 soluble tumor necrosis factor receptor; TNF 5 tumor necrosis factor.
Table 3. Results of Serum Urea, Creatinine Albumin and
Protein Estimations
Patients
(n 5 63)
Control
Subjects
(n 5 20)
p
Value*
Urea (mmol/liter) 9.74 6 5.60 5.71 6 1.23 0.002
Creatinine (mmol/liter) 128.9 6 53.1 90.7 6 8.3 0.002
Albumin (g/liter) 43.75 6 3.10 45.40 6 2.30 0.03
Total protein (g/liter) 70.33 6 4.43 67.05 6 2.74 0.002
*Unpaired t test comparisons between the two groups. Data presented are
mean value 6 SD.
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r 5 20.39, p , 0.001, respectively) (Fig. 2). There were similar
relations between V˙E/V˙CO2 slope and both sTNFR-1 and
sTNFR-2 (r 5 0.49, p , 0.001 and r 5 0.39, p , 0.001,
respectively). Although TNF was not significantly higher in the
patient group, it correlated with peak V˙O2 (r 5 20.34, p ,
0.002) and weakly with New York Heart Association (NYHA)
functional class (r 5 0.22, p , 0.05). There was a weak relation
between testosterone and DHEA (r 5 20.33, p , 0.001) but
not between testosterone and cortisol.
There was a negative correlation between body mass index
(BMI) and TNF levels (r 5 20.43, p , 0.001 for the patients
alone; r 5 20.40, p , 0.001 for the group as a whole). There
was a weak relation between BMI and the cortisol/DHEA ratio
(r 5 20.32, p 5 0.01 for the patients alone; r 5 20.25, p 5 0.03
for the group as a whole).
There was a relation between serum creatinine and
sTNFR-1 (r 5 0.70, p , 0.001), sTNFR-2 (r 5 0.60, p , 0.001)
and TNF (0.43, p , 0.001) (Fig. 3). These relations were much
stronger than those between serum albumin and sTNFR-1 (r 5
20.39, p , 0.001), sTNFR-2 (r 5 20.27, p 5 0.02) and TNF
(20.27, p 5 0.02).
Discussion
The weight loss of patients with chronic heart failure has
been recognized since earliest times (14), but the cause
remains obscure. A variety of abnormalities of cytokines have
been described (4,5) as has an increase in insulin resistance
(15) and an elevation in catabolic steroids in untreated patients
(16). This alteration in body metabolism suggests a possible
mechanism by which weight loss may occur. We wished to
assess the catabolic state in a group of patients with chronic
heart failure by measuring TNF and its receptors, and the ratio
of catabolic to anabolic steroid hormones.
In common with previous investigators (17), although the
TNF level was not significantly raised in the patient group, we
found an increasing level of TNF with worsening severity of
chronic heart failure as assessed by peak V˙O2 and NYHA
symptom class, although this association is weak. There were
stronger relations between clinical severity of heart failure and
levels of both TNF receptors. The level of TNF correlated
most closely with BMI. The ratio of catabolic to anabolic
steroid as measured by cortisol/DHEA ratio also correlated
with body mass.
The cause of the rise in catabolic factors is unclear. We
found that levels of TNF receptors correlated with serum
creatinine, suggesting a possible role for decreased excretion.
The role of soluble TNF receptors is not clear. They are
increased in chronic heart failure, whereas myocyte receptors
appear to be decreased (10). It may be that the elevated sTNF
receptor levels represent a reservoir of TNF in the circulation,
prolonging its biologic effects. The mechanisms by which
changes in cytokines and hormones might lead to loss of
muscle bulk are also unclear, but cytokine-induced pro-
grammed cell death may be occurring in skeletal muscle.
The patterns of steroid metabolism have not previously
been described in chronic heart failure. Alteration in the
cortisol/DHEA ratio may have important effects on the pat-
terns of immune activation (12), influencing the balance of T
helper cell maturation between T helper cell 1 and T helper
cell 2 pathways. The alteration in balance between anabolic
and catabolic steroids may have consequences for muscle
metabolism and wasting. We found the cortisol/DHEA ratio
correlated with body mass, and in tuberculosis, this relation
also appears to be related to loss of muscle bulk (11). TNF
release from macrophages appears to be affected by relatively
small changes in sex hormone concentration (18), but we did
not find a consistent pattern of alteration in sex hormone levels
in our group of patients.
Limitations to present study. This is an observational study
and cannot prove causal relations between levels of cytokines
and hormones and the progression of the heart failure syn-
drome and loss of muscle bulk. It may be that increased levels
of TNF and sTNFRs are merely reflections of severity of
illness. Given the present knowledge of the biologic effects of
these factors, it seems reasonable to suggest an etiologic role in
the muscle wasting associated with chronic heart failure.
We have measured total, rather than free, testosterone, and
Figure 2. Relation between sTNFR-1 and exercise capacity as mea-
sured by peak V˙O2.
Figure 3. Relation between levels of the two soluble TNF receptors
and serum creatinine.
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we may therefore have missed any relation between testoster-
one and other variables if significant variations in sex steroid
binding globulin were present. Our approach is inevitably
limited by the intrinsic circadian variability in some of the
substances measured and their sensitivity to environmental
changes. Little is known regarding the diurnal variation of
cytokine and steroid levels in chronic heart failure. For that
reason, we ensured that blood samples were drawn under
standard conditions at the same time of day in all subjects.
Further, levels of TNF, although elevated in chronic heart
failure, fluctuate markedly. In a study of 16 patients followed
up for .1 year (19), TNF was undetectable in every patient on
at least one occasion, although the sensitivity of the test kit
used was lower than that used in our study.
Conclusions. We found an increase in TNF and soluble
TNF receptors that correlates with severity of heart failure and
with body mass. In addition, we have shown an alteration in the
cortisol/DHEA ratio, suggesting a preferential effect of catab-
olism over anabolism. These changes may be causally related
to weight loss and muscle wasting in chronic heart failure.
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